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Compliance with Antimicrobial Therapy for Buruli Ulcer
S. Klis,a R. Kingma,a W. Tuah,b Y. Stienstra,a T. S. van der Werfa,c
Department of Internal Medicine, Infectious Disease Service, University Medical Center Groningen, Groningen University, Groningen, The Netherlandsa; Nkawie-Toase
Government Hospital, Nkawie, Ghanab; Department of Pulmonary Medicine and Tuberculosis, University Medical Center Groningen, Groningen, The Netherlandsc
We read with great interest the study by Philips et al. (1) re-porting on successful outcomes of the combination of
streptomycin and rifampin for 2 weeks, followed by clarithromy-
cin and rifampin for 6 weeks, in the treatment of Buruli ulcer
(BU). Currently, drug treatment for BU consists of 8 weeks of
intramuscular streptomycin and oral rifampin. However, several
recent studies, including the one by Philips et al., have described
good outcomes with (partly) oral therapy using rifampin and cla-
rithromycin (1–3), and a randomized controlled trial comparing
the standard treatment with fully oral therapy is under way (4).
Oral therapy is highly desirable, as intramuscular injections are
painful and administration is logistically complicated in a rural
African setting, sometimes forcing patients to travel several hours
daily for 8 weeks to the nearest health care facility. In addition,
streptomycin carries a considerable risk of toxicity (5).
These factors might negatively affect treatment compliance.
The current WHO-recommended strategy of early detection and
decentralization of treatment favors community-based care over
clinical admission. However, compared to hospital-based care,
ensuring compliance might be challenging, although the adher-
ence of BU patients under service conditions has never been stud-
ied. The WHO has issued a BU case record form that has been
widely used in the context of national programs, with precise re-
cording of the drug dosages administered. We reviewed these
forms at the BU clinic of Nkawie-Toase Hospital in Ghana. Of the
286 BU patients treated between 2008 and 2012, only 46% com-
pleted the recommended 56 doses of streptomycin and rifampin.
Noncompliance was significantly associated with self-referral, fe-
male gender, smaller lesions, and travel time.
We attempted to follow up on these noncompliers and were
able to locate 57 former BU patients. When asked for their reasons
for defaulting, 35% mentioned travel costs, 19% stopped coming
when their ulcers were healed, and 14% defaulted because of the
ototoxic adverse effects of streptomycin.
This large number of defaulters is perhaps not representative of
BU drug treatment in Ghana. Yet, these findings indicate that
noncompliance is in part related to streptomycin— because of
both its toxicity and the cumbersome and costly daily travel to the
health care facility for its administration. On the other hand, oral
therapy might present inherent challenges in terms of compliance,
as patients can be supplied with a full course of drugs to be taken at
home and patients will not be regularly seen at the health care
facility if no alternative form of directly observed treatment is
provided.
The possible transition to an oral regimen has many apparent
advantages but can pose a challenge to national programs and
local services in terms of compliance. Studies that combine or
compare oral and parenteral regimens, such as the one by Phillips
et al., can potentially shed more light on this issue, and we there-
fore urge authors of these studies to comment on their experiences
with compliance with both modes of treatment. In addition,
should oral therapy be implemented outside a research setting, we
suggest that compliance be systematically monitored.
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